Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

263
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
263
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

955
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
955
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

216
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
216
Inflammatory Response01:28

Inflammatory Response

15.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

371
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
371
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

176
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Securing the Future for a Major Academic Cardiovascular Program: Hardwiring a Referral Network and Preparing for a Transition to Value-Based Reimbursement.

Hospital topics·2020
Same author

Managing Cardiovascular Risk Factors without Medications: What is the Evidence?

Cardiovascular & hematological agents in medicinal chemistry·2020
Same author

Alcohol Excess Is an Insufficiently Considered Cause of Malignant Refractory Hypertension.

Angiology·2019
Same author

The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old.

Cardiovascular & hematological agents in medicinal chemistry·2019
Same author

Imaging Characteristics and Significance of Coronary Artery Mismatch Lesions.

Angiology·2019
Same author

Use and Value of Fractional Flow Reserve in Coronary Arteriography.

Angiology·2019

Related Experiment Video

Updated: Dec 22, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K

Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?

Thomas F Whayne1

  • 1Gill Heart and Vascular Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536-0200, USA. twhayn0@uky.edu.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|May 2, 2020
PubMed
Summary

Colchicine shows promise in reducing cardiovascular events in high-risk patients post-myocardial infarction. Further research is needed for widespread use, but it offers a potential anti-inflammatory strategy for cardiovascular disease prevention.

More Related Videos

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.1K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.7K

Related Experiment Videos

Last Updated: Dec 22, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.1K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.7K

Area of Science:

  • Cardiology
  • Inflammation Research
  • Pharmacology

Background:

  • Inflammation is increasingly recognized as a significant cardiovascular risk factor.
  • Standard care focuses on hypertension and low-density lipoprotein cholesterol (LDL-C) reduction.
  • The anti-inflammatory agent canakinumab has shown potential in reducing cardiovascular risk, sparking interest in other anti-inflammatory drugs.

Purpose of the Study:

  • To evaluate the evidence for colchicine, an established anti-inflammatory medication, in reducing cardiovascular risk.
  • To assess the role of colchicine in secondary cardiovascular event prevention.
  • To determine if colchicine provides cardiovascular benefits beyond current standard care.

Main Methods:

  • Review of meta-analyses and observational studies on colchicine's anti-inflammatory effects.
  • Analysis of the results from the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Assessment of evidence supporting colchicine for secondary prevention in high-risk cardiovascular patients.

Main Results:

  • Meta-analyses and observational studies suggest colchicine decreases cardiovascular risk due to its anti-inflammatory properties.
  • The COLCOT trial demonstrated a definite benefit of colchicine on cardiovascular outcomes in recent myocardial infarction patients.
  • Evidence supports colchicine for secondary prevention in high-risk individuals with persistent cardiovascular events despite optimal management.

Conclusions:

  • Colchicine is a viable option for secondary cardiovascular prevention in specific high-risk populations.
  • Further randomized controlled trials (RCTs) are required before recommending widespread use of colchicine for cardiovascular disease prevention.
  • Addressing acquisition cost issues is necessary for broader clinical adoption of colchicine.